Julio Delgado

Dr. Julio Delgado is the Head of the Onco-immunotherapy Unit and consultant haematologist at Hospital Clínic, Barcelona (HCB), researcher at IDIBAPS Biomedical Research Institute, and associate professor at the University of Barcelona. He has been involved in the clinical development of ARI-0001 (varnimcabtagene autoleucel), the first 100% academic CART-cell product ever approved under hospital exemption in an EU member state. He is a founding member of the Spanish Group for CLL and runs most CLL and CART-cell clinical trials at HCB. He is a core member of the EMA’s Scientific Advisory Group for Oncology, and advisor to the Spanish Medicines Agency and the Catalan Pharmacotherapy Committee. He is a member of HCB’s Advanced Therapies Committee and vice-president of the Institution’s Review Board/Ethics Committee. He is a past member of the EHA’s Education Committee and current member of the EHA’s European Affairs Committee. He has co-authored over 190 peer-reviewed papers.